Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
GSK supports recovery efforts to help those affected by the Japan earthquake
In response to events in Japan as a result of the Tohoku Kanto Earthquake and tsunami that devastated Japan's north east coastline region, GlaxoSmithKline (GSK) is supporting th...
Read more -
GSK announces positive topline results of Phase lll study of IPX066 in advanced Parkinson’s disease
GlaxoSmithKline (GSK) today announced positive, top-line results of the ADVANCE-Parkinson’s Disease (PD) Phase III clinical study, conducted by Impax Pharmaceuticals, of IPX066 ...
Read more -
GlaxoSmithKline and Tolerx announce phase III DEFEND-1 study of otelixizumab in type 1 diabetes did not meet its primary endpoint
GlaxoSmithKline (GSK) and Tolerx, Inc. today announced that the Phase III DEFEND-1 study of otelixizumab, an investigational humanised anti-CD3 monoclonal antibody, did not meet...
Read more -
GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta® (belimumab) for the treatment of systemic lupus erythematosus
GlaxoSmithKline plc (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that the U.S. Food and Drug Administration (FDA) has approved Benlysta (belimumab) for t...
Read more -
GlaxoSmithKline plc appoints two Non-Executive Directors to its Board (1)
GlaxoSmithKline plc (GSK) announces that Ms. Judy Lewent and Ms. Stacey Cartwright have been appointed as Non-Executive Directors and will join the Board of the Company with eff...
Read more -
Regulatory update: Nimenrix® (MenACWY vaccine)
GlaxoSmithKline (GSK) announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for its candidate conjugate mening...
Read more -
GSK outlines new plan to drive recruitment and attract graduate talent in the UK
GlaxoSmithKline (GSK) today outlined new plans to encourage talented students graduating from UK universities to consider pursuing a career within the company. These measures a...
Read more -
Reward for charities bridging gaps in health care provision
Ten UK charities have each won £25,000 in recognition of their outstanding contribution to improving health care. The charities beat more than 400 entrants to become winners of...
Read more -
World’s first everyday fluoride toothpaste with NovaMin® technology that can repair sensitive teeth
GlaxoSmithKline Consumer Healthcare, the maker of leading sensitive toothpaste brand Sensodyne, today announced a breakthrough in dental care with the launch of new Sensodyne Re...
Read more -
David Redfern appointed as new Chairman of ViiV Healthcare
GlaxoSmithKline (GSK), ViiV Healthcare, and Pfizer today announced the appointment of David Redfern as the new Chairman of the Board for ViiV Healthcare with effect from 1st Apr...
Read more -
GSK European regulatory update on Pandemrix™ (1)
CHMP concludes that data are insufficient to establish a causal relationship between Pandemrix and narcolepsy.
Read more -
First African country introduces GSK’s pneumococcal vaccine through innovative financing mechanism
GlaxoSmithKline (GSK) announced the incorporation of its pneumococcal vaccine into the Kenyan national immunisation programme. Kenya is the first African country to receive pneu...
Read more -
GlaxoSmithKline moving to new building at Philadelphia Navy Yard
GlaxoSmithKline (NYSE:GSK), a leading worldwide research-based pharmaceutical company, and Liberty Property Trust (NYSE:LRY) today announced that GSK has signed a 15.5-year leas...
Read more -
GSK revises US Avandia label to include new restrictions on use
GlaxoSmithKline (GSK) today announced revised US prescribing information and medication guides for all rosiglitazone-containing medicines (Avandia, Avandamet; and Avandaryl) to ...
Read more -
GlaxoSmithKline and Human Genome Sciences announce publication of BLISS-52 phase lll study results for Benlysta® in The Lancet
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced publication of the BLISS-52 study of Benlysta (belimumab) in autoantibody-positive patients...
Read more -
GSK results announcement for the fourth quarter
Strategic progress drives positive underlying sales growth*,increasing pipeline potential and improved cash generation. Increased dividend and new long-term share buy-back pr...
Read more -
GSK and Theravance announce progression of LAMA/LABA combination treatment into Phase III development for COPD
GSK and Theravance, Inc. today announced major milestones in two clinical development programmes focused on new treatments for patients with COPD, a leading cause of chronic ill...
Read more -
GSK announces the sale of its entire shareholding in Quest Diagnostics
GlaxoSmithKline plc (GSK) announces that it has sold its entire holding of 30,755,151 shares of common stock in Quest Diagnostics Inc. (Quest).
Read more -
Update on Pandemrix™ and interim Finnish report on narcolepsy
GSK is aware of today's interim report by the Finnish National narcolepsy committee on their investigation into reported cases of narcolepsy in Finland.
Read more -
GSK and Actelion discontinue clinical development of almorexant
GlaxoSmithKline (GSK) and Actelion Ltd (SIX: ATLN) today announced that clinical development of the Phase III investigational dual orexin receptor antagonist, almorexant, has be...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
